Trial
NCT05672199
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Efavaleukin alfa
Why stopped
The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-15